Neurological and MRI Screening Improves Long-term anti-TNF-alpha Treatment Safety in Patients with Crohn's Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10360982" target="_blank" >RIV/00216208:11130/17:10360982 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10360982

Výsledek na webu

<a href="http://www.prolekare.cz/en/czech-slovak-neurology-article/neurological-and-mri-screening-improves-long-term-anti-tnf--treatment-safety-in-patients-with-crohn-s-disease-60194?PLtoPLK=1" target="_blank" >http://www.prolekare.cz/en/czech-slovak-neurology-article/neurological-and-mri-screening-improves-long-term-anti-tnf--treatment-safety-in-patients-with-crohn-s-disease-60194?PLtoPLK=1</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Neurological and MRI Screening Improves Long-term anti-TNF-alpha Treatment Safety in Patients with Crohn's Disease

Popis výsledku v původním jazyce

Background: Several reports describe MRI signs of CNS demyelination in inflammatory bowel diseases (IBD) patients treated with monoclonal antibody against tumor necrosis factor alpha (anti-INF-alpha) and even indicate that anti-INF-alpha can trigger multiple sclerosis (MS). The first aim of the study was to evaluate the neurological status of Crohn&apos;s disease (CD) patients before anti-INF-alpha therapy initiation in order to avoid possible complications in patients with latent demyelinating diseases. Our second aim was to evaluate, by prospectively following their neurological and MRI status, the risk of developing CNS demyelination in patients with CD treated with anti-INF-alpha. Methods: Fifty patients, followed for more than 2 years, were included in the prospective phase of the study. Thirty of these patients were treated with anti-INF-alpha. Twenty patients without biological therapy were used as controls. Neurostatus and brain MRI were performed in all patients at baseline and after 1.5 years of treatment. CSF examination was performed if MRI raised suspicion of MS. Results: 54% of patients had abnormalities in neurostatus. MRI changes suggestive of demyelination were found in seven cases. In one patient, CSF-specific oligoclonal bands were found and anti-INF-a treatment was contraindicated. No changes in neurological or MRI status were observed after 1.5 years of treatment in either group. Conclusions: Preselection of patients at high risk of developing MS can increase the safety of anti-INF-alpha treatment.

Název v anglickém jazyce

Neurological and MRI Screening Improves Long-term anti-TNF-alpha Treatment Safety in Patients with Crohn's Disease

Popis výsledku anglicky

Background: Several reports describe MRI signs of CNS demyelination in inflammatory bowel diseases (IBD) patients treated with monoclonal antibody against tumor necrosis factor alpha (anti-INF-alpha) and even indicate that anti-INF-alpha can trigger multiple sclerosis (MS). The first aim of the study was to evaluate the neurological status of Crohn&apos;s disease (CD) patients before anti-INF-alpha therapy initiation in order to avoid possible complications in patients with latent demyelinating diseases. Our second aim was to evaluate, by prospectively following their neurological and MRI status, the risk of developing CNS demyelination in patients with CD treated with anti-INF-alpha. Methods: Fifty patients, followed for more than 2 years, were included in the prospective phase of the study. Thirty of these patients were treated with anti-INF-alpha. Twenty patients without biological therapy were used as controls. Neurostatus and brain MRI were performed in all patients at baseline and after 1.5 years of treatment. CSF examination was performed if MRI raised suspicion of MS. Results: 54% of patients had abnormalities in neurostatus. MRI changes suggestive of demyelination were found in seven cases. In one patient, CSF-specific oligoclonal bands were found and anti-INF-a treatment was contraindicated. No changes in neurological or MRI status were observed after 1.5 years of treatment in either group. Conclusions: Preselection of patients at high risk of developing MS can increase the safety of anti-INF-alpha treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká a slovenská neurologie a neurochirurgie

ISSN

1210-7859

e-ISSN

—

Svazek periodika

80

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

95-100

Kód UT WoS článku

000393627700018

EID výsledku v databázi Scopus

2-s2.0-85014571533